Company Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States.
Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease.
The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer.
The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016.
BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
| Country | United States |
| IPO Date | Sep 18, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Cuong Viet Do M.B.A. |
Contact Details
Address: 680 West Nye Lane Carson City, Nevada United States | |
| Website | https://bioviepharma.com |
Stock Details
| Ticker Symbol | BIVI |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001580149 |
| CUSIP Number | 09074F207 |
| ISIN Number | US09074F2074 |
| Employer ID | 46-2510769 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Cuong Viet Do M.B.A. | President, Chief Executive Officer & Director |
| Joanne Wendy Kim CPA | Chief Financial Officer, Treasurer & Corporate Secretary |
| Clarence N. Ahlem | Senior Vice President of Operations |
| Denise Smith | Senior Vice President of Manufacturing & Development |
| Dr. Christopher L. Reading Ph.D. | Senior Vice President of Alzheimer's Disease Program |
| Dr. Joseph M. Palumbo M.D. | Executive Vice President of R&D and Chief Medical Officer |
| Dr. Penelope Markham Ph.D. | Senior Vice President of Liver Disease Program |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 02, 2024 | 424B3 | Filing |
| Nov 27, 2024 | S-1/A | [Amend] Filing |
| Nov 22, 2024 | S-8 | Filing |
| Nov 21, 2024 | S-1 | Filing |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 08, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 424B5 | Filing |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |